Literature DB >> 6670711

Hyperargininemia: clinical course and treatment with sodium benzoate and phenylacetic acid.

N Mizutani, M Maehara, C Hayakawa, T Kato, K Watanabe, S Suzuki.   

Abstract

In a patient with hyperargininemia, oral administration of sodium benzoate or phenylacetic acid together with an essential amino acid mixture was used to prevent hyperammonemia and to decrease plasma and CSF concentrations of arginine. Sodium benzoate reduced the plasma ammonia levels, which was confirmed by the increase of urinary excretion of hippuric acid. Phenylacetic acid also controlled hyperammonemia, and EEG findings also improved. By these treatments, plasma and CSF concentrations of arginine showed a slight decrease, but were far above the normal range. There was no clinical improvement, and spasticity of the lower and upper extremities was progressive with mental deterioration.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6670711     DOI: 10.1016/s0387-7604(83)80059-x

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  3 in total

1.  Absence of erythrocyte arginase protein in Japanese patients with hyperargininemia.

Authors:  C Hayakawa; S Aono; H Keino; N Mizutani; K Watanabe; M Ikemoto; M Totani; T Murachi; S Kashiwamata
Journal:  Eur J Pediatr       Date:  1991-09       Impact factor: 3.183

2.  Three novel mutations in the liver-type arginase gene in three unrelated Japanese patients with argininemia.

Authors:  T Uchino; Y Haraguchi; J M Aparicio; N Mizutani; M Higashikawa; H Naitoh; M Mori; I Matsuda
Journal:  Am J Hum Genet       Date:  1992-12       Impact factor: 11.025

3.  Increased urinary excretion of putrescine in hyperargininaemia.

Authors:  T Kato; M Sano; N Mizutani; C Hayakawa
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.